Biofrontera Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	1.34	17.21	24.55	8.08	7.3
Short-Term Investments	0.08	10.55	0	0	0
Cash & Cash Equivalents	1.42	27.76	24.55	8.08	7.3
Cash Growth	-94.88%	13.08%	203.77%	10.65%	-
Receivables	5.16	7.41	12.43	3.29	4.79
Inventory	10.91	7.17	4.46	7.09	10.48
Other Current Assets	5.58	0.81	4.99	1.12	0.9
Total Current Assets	23.08	43.14	46.42	19.58	23.47
Property, Plant & Equipment	1.75	1.58	0.27	0.37	0.5
Goodwill and Intangibles	2.63	3.03	3.45	3.87	4.29
Other Long-Term Assets	0.48	3.13	3.08	0.32	0.49
Total Long-Term Assets	4.86	7.74	6.8	4.56	5.28
Total Assets	27.93	50.88	53.22	24.14	28.75
Accounts Payable	9.01	2.59	1.6	1.71	7.81
Current Debt	4.6	0.5	0	0	0
Other Current Liabilities	4.49	17.81	12.24	2.71	3.93
Total Current Liabilities	18.09	20.89	13.84	4.42	11.74
Long-Term Debt	0.8	0.85	0	0	38.2
Other Long-Term Liabilities	4.25	5.26	28.05	13.89	8.99
Total Long-Term Liabilities	5.05	6.11	28.05	13.89	47.19
Total Liabilities	23.14	27.01	41.88	18.31	58.93
Total Debt	5.4	1.35	0	0	38.2
Debt Growth	301.11%	-	-	-	-
Retained Earnings	-99.65	-79.52	-78.88	-41.17	-30.18
Shareholders' Equity	4.79	23.88	11.34	5.83	-30.18
Net Cash / Debt	-3.98	26.41	24.55	8.08	-30.9
Net Cash / Debt Growth	-	7.60%	203.77%	-	-
Net Cash Per Share	-2.57	24.99	55.73	7050.61	-617960.00
Working Capital	4.99	22.25	32.59	15.16	11.73
Book Value Per Share	3.10	22.59	25.74	5086.62	-603580.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).